Coeptis rises on licensing agreement to develop cancer cell therapies
11/03/2025 14:28
** Cancer therapy developer Coeptis Therapeutics' COEP.O shares rise 2.3% to $11.15 ** Co says it has licensed worldwide development and commercialization rights to cell therapy platform GEAR ** As part of the agreement with VyGen-Bio, Coeptis has formed a new majority-owned subsidiary, GEAR Therapeutics, to advance applications of the technology ** GEAR (Gene Edited Antibody Resistant) cell therapy platform modifies immune cells to effectively target and destroy cancer cells without being neutralized by antibodies taken during treatment ** Up to last close, COEP has risen 13.5% in the past 12 months (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))
Recent news on Z Squared (Delaware)
See all newsBrief: Z Squared Inc. Signs Definitive Agreement To Acquire 100% Of Paradox Data And Its Union County Campus
Brief: Z Squared, Inc. To Acquire Majority Interest In Paradox Data And Its Union County Campus, A Next-Generation Data Center Development Targeting Up To 150 MW Of Firm Power
Brief: Z Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement To Support Ai Infrastructure Buildout
Brief: Z Squared Appoints Jon Najarian, Pete Najarian, Marc Lopresti And Jay Zapata To Newly Formed Advisory Board
Brief: Z Squared Announces Executive Leadership Appointments To Advance Ai Infrastructure Strategy